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ABSTRACT 
Obstetric antiphospholipid syndrome (APS) is a systemic autoimmune disorder 
characterized by circulating antiphospholipid antibodies (aPL) and an increased risk of 
recurrent pregnancy loss and preeclampsia. Current treatments, such as low molecular 
weight heparin (LMWH) may maintain pregnancy but do not reduce the risk of these late 
gestational complications. aPL trigger placental inflammation by activating trophoblast 
Toll-like receptor 4 (TLR4), leading to cytokine production. Since some microRNAs 
(miRs) regulate TLR responses, this study sought to determine the functional role of 
aPL-induced miR expression in regulating trophoblast inflammation. Since vitamin D 
deficiency is common in APS patients, the effect of vitamin D on trophoblast function in 
the setting of aPL and LMWH was also evaluated. Thus, the human first trimester 
trophoblast cell line (HTR8) and primary trophoblast cultures were incubated with or 
without aPL in the presence or absence of vitamin D and/or LMWH. miR expression was 
profiled using RT-qPCR, and cytokine secretion was measured by ELISA. miR function 
was assessed by transfection of specific miR mimics or inhibitors. Indeed, treatment of 
trophoblast cells with aPL significantly upregulated expression of miR-146a-5p, miR-
146a-3p, miR-155, and miR-210 when compared to controls. Furthermore, miR-146a-5p 
and miR-146a-3p upregulation by aPL was TLR4 dependent. Functional studies 
demonstrated that miR-146a-3p directly promoted trophoblast IL-8 secretion by 
activating the RNA sensing receptor, TLR8. Vitamin D reduced aPL-induced miR-146a-
5p, IL-8 and LMWH-induced sFlt-1 release, but did not reduce aPL-induced miR-146a-
3p. These findings suggest that aPL induce trophoblast IL-8 production through 
upregulation of miR-146a-3p and subsequent activation of TLR8. Our findings also 
suggest that that vitamin D can dampen this inflammatory response downstream of miR-
146a-3p. Thus, further study of trophoblast miR function in the context of aPL and the 
therapeutic potential of vitamin D for obstetric APS is warranted. 
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 1 
INTRODUCTION 
 
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by a 
pro-thrombotic state and significant pregnancy morbidity. The disease is more common 
in women than men, and can present in isolation as primary systemic APS, or as 
secondary systemic APS in the context of another autoimmune disease such as 
systemic lupus erythematosus (SLE) (1). It is also the most common cause of acquired 
thrombophilia in the general population (2). Pregnant patients may develop obstetric 
APS, which increases the risk of both recurrent pregnancy loss (RPL) and late 
gestational complications such as preeclampsia, placental insufficiency and fetal growth 
restriction (1,3). Indeed, between 7 and 25% of RPL is attributable to APS (4), and 
nearly 50% of fetuses born to patients with APS are premature (5). Although the exact 
prevalence of APS is unknown, it is estimated to be between 40-50 cases per 100,000 
persons (6). Diagnosis of obstetric APS requires one or more of the following: 
unexplained death of a morphologically normal fetus beyond 10 weeks; preeclampsia 
necessitating delivery before the 34th week; or three or more consecutive abortions 
before the tenth week of gestation (7).  
 
Antiphospholipid antibodies and β2-glycoprotein I 
In addition to these clinical manifestations, the diagnosis of APS requires detection of 
persistently high titers of antiphospholipid autoantibodies (aPL) in the circulation (7). aPL 
are a heterogeneous population of autoantibodies that recognize anionic phospholipid-
binding proteins rather than phospholipids themselves (8,9). The prevalence of aPL has 
been difficult to assess due to heterogeneous patient populations and inconsistent 
laboratory protocols, however it is estimated that aPL are present in 1-4% of normal 
controls (10), 15.5% of women with RPL, and as high as 30% of women with fetal losses 
after 20 weeks (4). While anti-cardiolipin and lupus anticoagulant antibodies are included 
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in the diagnostic criteria, antibodies that target β2-glycoprotein I (β2GPI) are considered 
to be the most pathologic in obstetric APS (11-14).  
 
β2-glycoprotein I, also known as apolipoprotein H, is a highly abundant, highly 
glycosylated single chain polypeptide that circulates at a plasma concentration of 
200µg/mL (15). The protein consists of five sushi domains of approximately 60 amino 
acids, and aPL that react with domains I and V are of particular interest in obstetric APS 
(8,16,17). In vivo, β2GPI exists in two distinct conformations with different 
immunogenicities (18). The circular, or unbound form of β2GPI is not recognized by 
autoantibodies due to folding that hides the epitopes recognized by aPL. However, when 
bound to anionic surfaces, such as phospholipids, cardiolipin or phosphatidyl serine, 
β2GPI undergoes a conformational change that exposes critical regions, thereby 
allowing anti-β2GPI antibodies to bind (18). 
 
Anionic phospholipids are rarely physiologically exposed on the outer surface of the cell 
membrane, and β2GPI-autoantibodies do not bind free β2GPI in serum (18). However, 
because the placenta undergoes extensive proliferation and remodeling, anionic 
phospholipids become exposed on the trophoblast surface, allowing exogenous β2GPI to 
bind the trophoblast under physiologic conditions (9,19,20). Furthermore, the trophoblast 
constitutively express β2GPI, independently making the placenta a target of aPL (21). 
However, the direct implication of β2GPI in aPL-mediated pregnancy loss was 
highlighted by Roberston et al. using a mouse model; by passively immunizing both 
wildtype and β2GPI-null pregnant mice with human aPL, it was demonstrated that 
functioning β2GPI is not required for the maintenance of pregnancy, but is necessary for 
the development of aPL-induced pregnancy loss (14). Thus, β2GPI plays a critical role in 
the pathophysiology of obstetric APS.  
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Antiphospholipid antibodies, inflammation and trophoblast function 
Given that systemic APS is a pro-thrombotic disease, adverse pregnancy outcomes 
associated with APS were initially attributed to clotting at the maternal-fetal interface. 
This notion was initially supported by the apparent beneficial effect of heparin in 
reducing fetal loss in APS patients (22-24). However, evidence of placental thrombosis 
on histologic examination of APS miscarriage samples is uncommon (25). More 
frequently, disruptions in placentation are identified, such as reduced endovascular 
trophoblast invasion and impaired maternal spiral artery transformation (25,26). 
Evidence of inflammation is also common in these samples, and numerous groups have 
identified inflammatory processes as mediators of aPL-induced pregnancy loss (27-31). 
Thus, pregnancy complications associated with APS may due to placental dysfunction 
and inflammation, rather than intravascular thrombosis. Indeed, this hypothesis has 
been supported by both in vitro and animal studies using aPL. For example, in mice 
exposed to high levels of human aPL, elevated pro-inflammatory TNFα levels are found 
both systemically and in decidual tissue where aPL localize, resulting in increased fetal 
resorption (28). Importantly, blockade of this TNFα response reduces fetal resorption to 
baseline levels. Furthermore, in concurrence with histologic findings (25), both 
monoclonal and patient-derived aPL have been shown to reduce trophoblast migration 
and invasion in vitro (32,33). Taken together, these data suggest that inflammation and 
altered trophoblast function due to aPL are instrumental in APS pathogenesis.  
 
Antiphospholipid antibodies and Toll-like receptors 
While the mechanisms underlying these processes were initially unclear, the observation 
made by Raschi et al. identifying similarities between endothelial cell responses to aPL 
and bacterial lipopolysaccharide (LPS) suggested interactions between β2GPI and the 
prototypical innate immune receptor, Toll-like receptor 4 (TLR4) (34). Toll-like receptors 
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are a group of highly conserved pattern recognition receptors that recognize a wide 
variety of ligands associated with pathogens, known as pathogen-associated molecular 
patterns (PAMPs), as well as some host-derived danger signals, known as damage-
associated molecular patterns (DAMPs). PAMPs, such as LPS, are not expressed by 
humans, which allows for rapid and specific identification of microbes by immune cells. 
DAMPs are endogenous molecules that, following tissue injury, are released from their 
physiologic compartments and become exposed to and recognized by the immune 
system. TLRs recognizing either PAMPs or DAMPs subsequently trigger innate immune 
responses critical to both immediate defense against pathogens and development of 
adaptive immunity. The 10 known human TLRs share the same type I transmembrane 
glycoprotein structure, each consisting of extracellular and transmembrane domains and 
an intracellular signaling domain. Physiologically, TLR4 is responsible for sensing LPS 
expressed on the surface of gram-negative bacteria. When bound to LPS, TLR4 
homodimerizes, allowing recruitment of the adapter protein myeloid differentiation factor 
88 (MyD88) and subsequent activation of downstream signaling proteins interleukin-1 
receptor-associated kinase 1 (IRAK1) and tumor necrosis factor receptor-associated 
factor 6 (TRAF6), ultimately triggering nuclear factor κB (NF-κB) -dependent 
transcription of inflammatory genes (35).  
 
In recent years, the ability of TLR4 to interact with endogenous ligands such as β2GPI in 
a pathological context has been explored. In endothelial cells, which do not produce 
β2GPI, serum-derived β2GPI binds to cell surface receptors ApoER2, allowing 
autoantibodies to interact with β2GPI. This results in endothelial cell activation and 
increased cell adhesion (36-38). Moreover, these aPL-mediated effects are dependent 
on TLR4/MyD88-dependent signaling (34,39,40). Similar results have been found in 
monocytes, where anti-β2GPI antibodies induce co-localization of TLR4 and β2GPI to 
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lipid rafts, leading to TLR4 activation and subsequent NF-κB-dependent gene 
transcription (41). This ability to activate TLR4 signaling is thought to be due to shared 
epitopes between β2GPI and LPS. To that end, Blank et al. illustrated that mice 
immunized with bacterial products produce anti-β2GPI antibodies capable of inducing 
fetal loss, suggesting that molecular mimicry results in production of anti-β2GPI-
antibodies that recognize epitopes common to β2GPI and LPS (42). Since the 
trophoblast constitutively express β2GPI, and are likely targeted by circulating aPL in the 
earliest stages of placentation, our group has worked to address the mechanisms by 
which aPL alter human first trimester trophoblast function. 
 
Similar to the observations made in endothelial cell and monocyte systems, we 
described the ability of anti-β2GPI antibodies to induce human first trimester trophoblast 
responses through both TLR4/MyD88 -dependent and -independent pathways (30). 
Specifically, it was demonstrated that anti-β2GPI antibodies elicit TLR4/MyD88-
dependent trophoblast secretion of inflammatory cytokines: interleukin-8 (IL-8), growth 
related oncogene-α, monocyte chemoattractant-1 and interleukin-1β (IL-1β)(30). Recent 
work by our lab has further shown that the IL-1β response in the trophoblast is 
dependent on TLR4-mediated uric acid production, which in turn activates the 
Nalp3/ASC inflammasome, leading to IL-1β processing and release (43). However, the 
IL-8 response was shown to be independent of the inflammasome, and the mechanisms 
by which the other cytokines are regulated remain unclear. Nonetheless, the observed 
upregulation of IL-8 and IL-1β by aPL provides a potential mechanism for the recruitment 
of neutrophils to the placenta observed in APS miscarriage samples (27). Furthermore, 
in parallel to these inflammatory responses, anti-β2GPI antibodies modulate human first 
trimester trophoblast secretion of angiogenic factors, including upregulation of the pro-
angiogenic factors, vascular endothelial growth factor (VEGF), placental growth factor 
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(PlGF), and the anti-angiogenic factor soluble endoglin (sENG) (44-47). Interestingly, 
this occurs via both MyD88-dependent (PlGF) and independent processes (VEGF, 
sENG). In addition, anti-β2GPI antibody induces the downregulation of basal interleukin-
6 (IL-6) production, which subsequently inhibits STAT3 activity resulting in decreased 
trophoblast migration in vitro. Furthermore, aPL upregulate trophoblast expression of the 
matrix metalloproteinase inhibitor TIMP-2, which further contributes to this inhibition of 
cell migration (45). Since precise regulation of cytokines, chemokines, and angiogenic 
factors is required for development of a functional maternal-fetal interface, even minor 
changes in the milieu may result in damaging inflammation and impaired invasion and 
vascular remodeling that lead to the pathological sequelae observed in APS.  
 
Current APS therapies and the trophoblast 
Currently, pregnant women with APS are treated with low molecular weight heparin 
(LMWH), either alone or in combination with aspirin (22,23,48). While this treatment 
approach might reduce the risk of RPL, the occurrence of late-term obstetrical 
complications such as preeclampsia remains high (22,23,48). To date, clinical and 
experimental studies have produced contradictory results regarding the effectiveness of 
LMWH and aspirin in preventing aPL-associated adverse pregnancy outcomes (48-54), 
and in being able to reverse the detrimental effects of aPL on trophoblast function in vitro 
(30,55-58). Studies from our group have shown that aspirin has no beneficial effects on 
aPL-modulation of trophoblast function (59).  While successfully reducing aPL-mediated 
upregulation of IL-8 and IL-1β, LMWH has no beneficial effect on aPL-reduced 
trophoblast migration or altered angiogenic factor secretion. Moreover, LMHW induces a 
robust elevation of trophoblast sFlt-1 release, even in the absence of aPL (30,32,44,46). 
Similar elevations of sFlt-1 have been observed in placental villus explants (60-62) and 
in pregnant women treated with LMWH (61,62). Since sFlt-1 is a potent anti-angiogenic 
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factor that is thought to be a mediator of end-organ damage in preeclampsia (63,64), it is 
clear that LMWH may have both beneficial and deleterious effects on the trophoblast. 
This may explain the inability of LMWH to reverse the late gestational complications 
associated with APS, such as preeclampsia, despite its relative success in prolonging 
pregnancy. Undoubtedly, the mixed effects of LMWH highlight the need to identify 
alternative therapeutic targets and treatments for the management of obstetric APS. 
 
Vitamin D, the immune system and the trophoblast 
In recent years, the biologically active form of vitamin D, 1,25-dihydroxyvitamin D 
(vitamin D), has been found to have numerous immunomodulatory effects in addition to 
its classical role in calcium homeostasis. Vitamin D is a steroid hormone produced from 
endogenous and dietary precursors that controls gene regulation through interaction with 
the vitamin D receptor (VDR) (65). When vitamin D binds the VDR in the nucleus, the 
resulting dimer acts as a transcription factor to upregulate genes controlled by the 
vitamin D response element (65). Interestingly, the first evidence of vitamin D’s ties to 
the immune system came from observations in patients with sarcoidosis, whose 
elevated vitamin D levels were attributed to increased synthesis in disease-associated 
macrophages (66,67). Since then, VDR expression has been identified in both immune 
and non-immune cells alike, including the trophoblast (68-70), and the placenta has 
been identified as a major site of vitamin D activation (71). Although conflicting data 
exist, it has been suggested that vitamin D broadly influences T-cell maturation and 
function, preferentially shifting T-cell cytokine responses away from cell-mediated 
immunity (Th1) towards humoral immunity (Th2), therefore potentially limiting tissue 
damage caused by inflammation (72). Furthermore, vitamin D deficiency has been 
directly implicated in the pathogenesis of APS since Vitamin D can inhibit anti-β2GPI 
antibody-mediated tissue factor expression in endothelial cells (73). Recently, 
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interactions between TLRs and vitamin D have been demonstrated, including the 
upregulation of CYP27B1, the enzyme responsible for activating vitamin D, by TLR4 
signaling (68,74). Moreover, treatment of murine placental explants with vitamin D 
results in attenuation of inflammatory cytokines induced by the TLR4 ligand LPS (71). 
Interestingly, population studies suggest vitamin D deficiency may be associated with 
APS and SLE (75,76), and also with adverse pregnancy outcomes such as 
preeclampsia (77-79) and recurrent pregnancy loss (80). Thus, vitamin D 
supplementation represents a promising adjunct for treating pregnant women with APS 
(73), particularly since aPL induced placental inflammation is TLR4-mediated (11,81). 
 
Toll-like receptors and microRNAs 
In the physiologic state, TLRs and their respective downstream signaling pathways must 
be tightly regulated to allow for a robust inflammatory response while ensuring 
appropriate attenuation in order to prevent subsequent tissue injury. One proposed 
mechanism of such precise regulation is through microRNAs (miRs). miRs are small, 
noncoding RNAs that regulate protein expression through post-transcriptional interaction 
with mRNA, either by suppressing translation, or reducing levels of target mRNA (82,83). 
miRs are highly conserved among mammalian species and can target hundreds of 
distinct mRNAs, thus expression of most genes is likely under some degree of control by 
miRs. Indeed, many miRs have been identified that both regulate and are induced by 
TLR signaling (82).  Therefore, miRs are well poised to act in a negative feedback 
mechanism of control over TLR genes. Indeed, recent studies have revealed a number 
of miRs that specifically target elements of the TLR4 signaling pathway; these include 
miR-9, which targets NF-κB (84); miR-146a-5p (formerly designated miR-146a), which 
targets IRAK1 and TRAF6 (85); and miR-155, which targets MyD88 (86). While these 
studies were conducted in other cell types, altered miR expression has been identified in 
 9 
trophoblast exposed to hypoxia, environmental toxins or LPS, and in placentas from 
pathological pregnancies (87-89). Interestingly, vitamin D has been shown to alter levels 
of miR-146a-5p and miR-155 in the serum (90), and thus likely modulates intracellular 
levels as well. To date, little is known about the role of miRs in trophoblast function, and 
no information exists on whether aPL-induced responses may be regulated by miRs. 
Thus, aPL may indeed be exerting its effects on trophoblast function through modulation 
of miR expression, leading to changes in the TLR4/MyD88 signaling pathway. 
Therefore, my central hypothesis is that aPL decrease trophoblast miR 
expression, allowing activation of the TLR4/MyD88 pathway and the subsequent 
alteration of trophoblast function, and that vitamin D reverses these effects. The 
mechanisms by which aPL affect trophoblast function still remain largely unclear, and 
current therapies do not reduce the risk of severe late gestational pregnancy 
complications. Therefore, a better understanding of the pathophysiology of obstetric APS 
is needed to identify novel targets for pharmacotherapy. The overall goals of this study 
were to: 1) characterize the effects of aPL on trophoblast miR expression and function; 
and to 2) investigate the effects of vitamin D on trophoblast function and miR expression 
in the setting of aPL and LMWH. Thus, the specific objectives of this project were: 
1. To determine the effects of aPL on miR expression in first trimester trophoblast 
cells. 
2. To determine the functional role of miRs in the regulation of trophoblast 
responses to aPL. 
3. To determine the potential of therapeutic vitamin D to reverse aPL-mediated 
effects on trophoblast function and miR expression.  
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MATERIALS AND METHODS 
 
Reagents 
The low molecular weight heparin (LMWH) preparation, Lovenox (Enoxaparin), was 
obtained from Aventis Pharmaceuticals Inc. (Bridgewater, NJ, USA). Active vitamin D 
(1,25-Dihydroxyvitamin D3) was obtained from Sigma-Aldrich, (St Louis, MO, USA), 
reconstituted in ethanol and filter sterilized prior to use. The TLR4 antagonist, LPS from 
R. sphaeroides (LPS-RS) was purchased from Invivogen (San Diego, CA). 
 
Antiphospholipid antibodies 
The current study utilized two mouse IgG1 anti-human β2GP1 monoclonal antibodies 
(aPL), designated ID2 and IIC5, which were produced by one of our collaborators (L.W. 
Chamley), under sterile conditions and filter sterilized prior to use. The antibodies were 
cloned from mice immunized with purified human β2GPI, and have been previously 
characterized (91). Like patient-derived polyclonal aPL, ID2 and IIC5 bind β2GPI when it 
is immobilized on a negatively charged surface such as phospholipids, cardiolipin, 
phosphatidyl serine or irradiated polystyrene (92). Moreover, ID2 and IIC5 react 
specifically with epitopes within domain V of β2GPI (45), and have been shown to bind to 
human first trimester trophoblast cells and alter their function in a similar fashion to 
patient-derived polyclonal aPL (30,43,44). A mouse IgG1 monoclonal antibody (BD 
Biosciences, San Jose, CA) was used as an isotype control.  
 
 
Isolation of primary trophoblast cells from first trimester placenta 
First trimester placentas (7-12 weeks gestation) were obtained from elective 
terminations of normal pregnancies performed at Yale-New Haven Hospital. The use of 
patient samples was approved by Yale University’s Human Research Protection 
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Program. Tissue specimens were washed with cold Hanks Balanced Salt Solution 
(Gibco) to remove excess blood, minced, transferred to trypsin-EDTA (Invitrogen, 
Carlsbad, CA, USA) digestion buffer and incubated at 37°C for 40 min with shaking. The 
mixture was then passed through a nylon strainer and then layered over Lymphocyte 
Separation Media (ICN Biomedicals, Inc., Aurora, OH, USA) and centrifuged at 400 × g 
for 25 min. The cellular interface containing the trophoblast cells was collected and 
resuspended in D-MEM with D-valine (Caisson Labs, North Logan, UT, USA) 
supplemented with 10% normal human serum (Gemini Bio-Products, Woodland, CA, 
USA) and cultured at 37°C/5% CO2 as previously described (30,44,47).  
 
Human first trimester trophoblast cell lines 
The human first trimester extravillous trophoblast cell line, HTR8, was used in these 
studies. The HTR8 cells were immortalized by SV40 (93) and were a kind gift from Dr. 
Charles Graham (Queens University, Kingston, ON, Canada). HTR8 cells were cultured 
in RPMI 1640 (Gibco, Carlsbad, CA, USA), which was supplemented with 10% fetal 
bovine serum (Hyclone, South Logan, UT, USA), 10 mm Hepes, 0.1 mm MEM non-
essential amino acids, 1 mm sodium pyruvate, and 1000U/ml/1000ug/ml 
penicillin/streptomycin (Gibco). Cells were maintained at 37°C⁄5% CO2 and passaged 
between 80%-100% confluency by trypsinization, centrifugation and resuspension. The 
TLR8 dominant negative (TLR8-DN) trophoblast cells were previously produced from 
HTR8 cells stably transfected with the pZERO plasmid containing the TLR8-ΔTIR gene 
(Invivogen). Without the TIR domain, the TLR8 protein maintains ligand affinity but is 
unable to induce signaling cascades. Briefly, cells were transfected overnight with 2µg of 
DNA using Fugene 6 (Roche Diagnostics, Indianapolis, IN). Following transfection, cells 
were allowed to recover in growth media for 24hrs, after which selection for stable 
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expression was performed using 250µg/mL of puromycin (Invivogen). The TLR8-DN 
trophoblast cell-line has been previously characterized (94). 
 
Trophoblast cell treatment experiments and transfections 
For all experiments, confluent cells were trypsinized, plated into 60mm dishes at 2.0 × 
105 cells/mL and allowed to adhere overnight. Cells were then treated with or without the 
aPL ID2, IIC5 or an IgG1 isotype control (20µg/mL) in serum-free Opti-MEM media 
(Gibco). For vitamin D and LPS-RS experiments, cells were pre-treated with either 10nM 
active vitamin D or 10µg/mL LPS-RS 1 hour prior to treatment with aPL. Isolated primary 
trophoblast cells were treated with no treatment (NT) or with the aPL, ID2 (20µg/ml) in 
the presence or absence of LMWH (100µg/ml), vitamin D (10nM), or a combination of 
both LMWH and vitamin D. Dosages of vitamin D and LMWH were determined from 
previous studies (30,44,46,58,69), and assessed for toxicity using the Celltiter 96™ 
viability assay prior to use. Neither the treatments nor the ethanol control had any effect 
on cell viability (data not shown).  
 
To assess miR function, cells were transfected with 100nM of either an anti-miR 
scramble sequence control or specific inhibitors of miR-146a-5p, miR-146a-3p, miR-155, 
or miR-210 (Anti-miR, Life Technologies, Grand Island, NY), using siPORT NeoFX 
transfection reagent (Invitrogen, Grand Island, NY). Similarly, cells were transfected with 
a specific miR-146a-5p precursor, miR-146a-3p precursor, or a scramble sequence 
control at 200nM (Pre-miR, Life Technologies, Grand Island, NY). Transfection efficiency 
in excess of 99% was assured using Cy-3 labeled anti-miR scramble sequence control 
and direct visualization under fluorescence microscopy.  
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Migration studies 
Trophoblast migration was assessed using the two-chamber QCM Colorimetric Cell 
Migration Assay (EMD Millipore, Billerica, MA) as previously described (32). Briefly, 
HTR8 trophoblast cells were transfected using specific inhibitors of miR-155, or miR-210 
or a scramble control as above. After 24h, transfected cells were trypsinized and 1 × 105 
cells in 200µL were placed into cell culture inserts with 8µm pores in the presence or 
absence of aPL (20µg/mL). The inserts were then placed into 24-well culture plates, with 
each well containing 800µL of either OptiMEM (NT), or aPL (20µg/mL). 1 × 105  cells in 
1mL were also placed directly into the 24-well plate to serve as a 100% migration 
control. After 48h of treatment, migrated cells were stained and lysed according to the 
manufacturer’s protocol. Stained lysates were then transferred to a 96-well plate in 
triplicate and optical densities were measured using the iMArk Microplate Absorbance 
Reader  (BioRad, Hercules, CA) and compared to the 100% migration control. 
 
Cytokine and angiogenic factor studies 
After 72hrs in treatment, trophoblast cell-free culture supernatants were collected by 
centrifugation at 1500 × g for 10 min at 4°C stored at -80°C. The pro-inflammatory 
cytokines, IL-8, IL-6 and IL-1β; the pro-angiogenic factors, VEGF and PlGF; and the anti-
angiogenic factors, sENG and sFlt-1 were measured in the supernatants by ELISA 
(Enzo Life Sciences, Farmingdale, NY, USA or R&D Systems, Minneapolis, MN, USA) 
following the manufacturers’ protocols directly.  
 
RNA isolation and quantitative real-time qPCR 
 
After 6-48h in culture, trophoblast cellular RNA was extracted using TRIzol (Life 
Technologies). Briefly, supernatants were removed and 1 mL of TRIzol was added to 
adherent cells for 5 min on ice. Cells were then scraped and transferred to 1.5 mL tubes, 
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vortexed, and combined with 200µL chloroform. Samples were vortexed, incubated at 
RT for 5 min and then centrifuged at 13000 × g for 15 min at 4°C. The aqueous phase 
was then collected, combined with 500 µL isopropanol and allowed to precipitate 
overnight at -20°C. RNA was then pelleted by centrifugation at 13000 × g for 10 min at 
4°C and resuspended in RNAse free water. Total RNA concentration was then 
measured using the NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, 
MA). The expression of miR-9, miR-146a-5p, miR-146a-3p, miR-155, miR-210, and let-
7c were assessed using the Taqman MicroRNA Assay (Life Technologies) and 
normalized to the endogenous control snU6. Briefly, 10ng of total RNA was reverse 
transcribed using Taqman reverse transcriptase kit in a reaction volume of 15µL 
containing 3µl of primers specific for miR-9, miR-146a-5p, miR-155, miR-210, and let-7c 
using the following thermal cycling conditions: 16°C for 30min, 42°C for 30min, 85°C for 
5min. For miR-146a-3p, 250ng of total RNA were reverse transcribed as above, and 
then pre-amplified using Taqman PreAmp master mix kit (Life Technologies) for 10 
cycles according to the manufacturer’s protocol. The resulting cDNA was then amplified 
using Taqman Universal PCR Master Mix II with UNG (Life Technologies) and specific 
primers for target miRs under the following conditions: 50°C for 2min, 95°C for 10min, 
95°C for 15sec and 60°C for 60sec. Data were analyzed using the Δ-Δ CT method and 
plotted as fold change (FC) in the expression of gene of interest normalized to the 
endogenous control.  
 
 
Statistical analysis 
Experiments were performed a minimum of three times and assayed in duplicate. Data 
were then pooled and are expressed as mean ± SEM. Statistical significance (p<0.05) 
was determined by Student’s t-test or analysis of variance (ANOVA) where appropriate 
using Prism software (Graphpad Software inc, La Jolla, CA). 
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RESULTS 
 
aPL upregulate trophoblast expression of miR-146a-5p, miR-155, and miR-210 
 
Since the effects of aPL on trophoblast expression of miRs have yet to be studied, the 
first objective of this study was to characterize first trimester trophoblast expression of 
miRs in response to aPL. To accomplish this, we utilized a well-characterized in vitro 
system consisting of a human first trimester trophoblast cell line (HTR8) and the mouse 
anti-human β2GPI monoclonal antibody, IIC5 (aPL). Previous work from our lab has 
shown that aPL induce a pro-inflammatory response in the trophoblast by binding β2GPI 
and activating the TLR4/MyD88 pathway (30). Therefore, a panel of five miRs known to 
be involved in TLR signaling was selected for initial analysis; miR-146a-5p, miR-155, 
and miR-9 are known to target IRAK/TRAF6, TAB2 and NF-κB/p50 of the TLR4 
signaling pathway, respectively (82). The panel also included two miRs known to affect 
trophoblast function; miR-210, which inhibits trophoblast migration and is induced by 
TLR3, and Let-7c, which inhibits trophoblast IL-6 secretion and is induced by TLR2 (95-
98). Given that these miRs are also known to be induced by TLR signaling and inhibit 
migration, we postulated that treatment with aPL would alter their expression in the 
trophoblast. First, we conducted a preliminary time course study evaluating miR 
expression in the HTR8 trophoblast cell line in response to aPL between 6-48h. As 
shown in Figure 1A, miR-146a-5p was significantly elevated at 48h (p<0.05). miR-155 
and miR-210 exhibited a similar trend, but were not significantly elevated (Figure 1A). 
Having established that 48h was the optimal time point, further experiments were 
performed using full controls. As shown in Figure 1B, after 48h of treatment, aPL 
induced a significant upregulation of trophoblast miR-146a-5p, miR-155 and miR-210, 
when compared to the no treatment (NT) control. In contrast, no significant changes in 
expression of miR-9 or let-7c in response to aPL were identified. No significant alteration 
in miR-146a-5p, miR-155, miR210, miR-9 or Let-7c expression levels was observed in 
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response to the mouse IgG1 isotype control, suggesting that the responses observed 
were specific to aPL (Figure 1B).  
 
 
Figure 1. aPL induce cellular expression of miR-146a-5p, miR-155 and miR-210, but not 
miR-9 or Let 7c.  
Trophoblast cells (HTR8) were treated with either no treatment (NT), aPL (20µg/mL) or 
IgG isotype control (20µg/mL). After 6-48h (A) or 48h (B), cellular RNA was isolated 
and analyzed for miR-146a-5p, miR-155, miR210, miR-9 and Let-7c expression by 
qPCR using snU6 as an internal control. Data were analyzed by ANOVA and 
expressed as fold change (FC) relative to the NT control. A: n=1-4, B: n=10. *p<0.05. 
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aPL-induced trophoblast expression of miR-146a-5p, but not miR-155 or miR-210, 
is TLR4 dependent 
 
Since aPL induce a pro-inflammatory response in the trophoblast through TLR4 (30) and 
a number of miRs can be induced after TLR activation (82), the next objective of this 
study was to determine the role of TLR4 in the observed induction of trophoblast miR 
expression by aPL. To test this, trophoblast cells were treated with aPL in the presence 
or absence of the TLR4 competitive antagonist LPS-RS. As shown in Figure 2, addition 
of LPS-RS to the culture resulted in a significant attenuation of aPL-induced miR-146a-
5p expression from a 1.9 fold to 1.4 fold increase (p<0.05), suggesting that this response 
is TLR4 mediated. aPL-induced expression of miR-155 and miR-210 was not 
significantly altered by LPS-RS (Figure 2).  
 
Figure 2. aPL-induced miR-146a-5p expression is inhibited by LPS-RS 
Trophoblast cells (HTR8) were treated with either media or LPS-RS (10µg/mL) and 
then incubated with or without aPL (20µg/mL) for 48h. Cellular RNA was isolated and 
analyzed for miR-146a-5p, miR-155 and miR210 by qPCR using snU6 as an internal 
control. Data were analyzed by student’s t-test and expressed as fold change (FC) 
relative to the untreated control. n=4, *p<0.05. 
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aPL upregulate trophoblast expression of miR-146a-3p in a TLR4 dependent 
manner 
 
Given that only miR-146a-5p expression was found to be TLR4-mediated, we decided to 
focus the remainder of our studies on miR-146a expression and function. In this regard, 
we evaluated both the dominant miR-146a-5p form, as well as its isomiR, miR-146a-3p 
(formerly miR-146a*). Initially thought to be responsible solely for ensuring accurate 
processing of the dominant miR, isomiRs, or miR*s, have been reexamined in a 
functional context after being found to be evolutionarily conserved and to have 
regulatory activity (99,100). Recent studies suggests that despite expression levels often 
20-200 fold lower than their miR counterparts, isomiRs can associate with the RNA-
induced silencing complex and interact with mRNA, further suggesting that they may 
serve a functional role (100,101). Thus, we next examined the effects of aPL on 
trophoblast miR-146a-3p expression. Similarly to miR-146a-5p (Figure 1B), miR-146a-3p 
expression was significantly upregulated 7.5 fold in response to aPL (p<0.05) compared 
to the no treatment (NT) control (Figure 3A). The mouse IgG1 isotype control had no 
effect on miR-146a-3p expression. Furthermore, aPL-induced miR-146a-3p expression 
was significantly reduced from 12.3 to 6.8 fold in the presence of LPS-RS (Figure 3B; 
p<0.05), suggesting that miR-146a-3p is regulated by TLR4, similar to miR-146a-5p. 
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Figure 3. miR-146a-3p expression is induced by aPL and this is inhibited by LPS-
RS. (A) Trophoblast cells (HTR8) were treated with either no treatment (NT), aPL 
(20µg/mL) or IgG isotype control (20µg/mL). (B) Trophoblast cells (HTR8) were treated 
with or without aPL (20µg/mL) in the presence of media or LPS-RS (10ug/ml). After 
48h, cellular RNA was isolated and analyzed for miR-146a-3p by qPCR using snU6 as 
an internal control. Data are expressed as fold change (FC) relative to the NT control. 
(A) n=8; *p<0.05 as determined by ANOVA; (B) n=7; *p<0.05 as determined by 
Student’s t test. 
 
 
 
Inhibition of trophoblast miR-146a-3p reduces aPL-induced IL-8 secretion 
 
The end result of TLR activation is marked by production of pro-inflammatory cytokines 
and chemokines, which are transcribed by RNA polymerase II-sensitive genes (102). 
miRs are also transcribed by RNA polymerase II and thus can be induced by TLR 
signaling (103). Therefore, expression of miRs can be both a product and a target of 
TLR signaling. Since miR-146a-5p is known to inhibit IRAK1/TRAF6 of the TLR4 
signaling pathway, we postulated that inhibition of aPL-induced miR-146a-5p expression 
in the trophoblast would result in unrestrained TLR4 signaling and a further increase in 
TLR4 end-function responses to aPL. Currently, no information exists on the functional 
role of miR-146a-3p, although it has been implicated the development of thyroid cancer 
(104). Thus, we transfected HTR-8 trophoblast cells with specific inhibitors to miR-146a-
5p and miR-146a-3p in the presence or absence of aPL, and subsequently measured IL-
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8 secretion, well-established by our lab as a marker of aPL-mediated TLR4 signaling 
(30). Interestingly, transfection of trophoblast cells with a miR-146a-3p inhibitor resulted 
in a significant reduction in aPL-induced trophoblast IL-8 secretion from 3.6 fold to 2.1 
fold, as compared to the miR scramble control (p<0.05) (Figure 4A). However, there was 
no significant effect of miR-146a-5p inhibition on aPL-induced trophoblast IL-8 secretion 
(Figure 4B).  
 
Figure 4. Inhibition of miR-146a-3p decreases aPL-mediated trophoblast IL-8 
secretion. Trophoblast cells (HTR8) were transfected with a miR scramble control and 
either (A) a miR-146a-3p inhibitor (α-miR-146a-3p; 100nM) (n=10), or (B) a miR-146a-
5p inhibitor (α-miR-146a-5p; 100nM) (n=4). Following transfection, cells were treated 
with or without aPL (20µg/mL). After 72h, cell-free supernatants were collected and 
measured for IL-8 secretion by ELISA. Data were analyzed by Student’s t-test and 
expressed as fold change (FC) relative to the untreated control; *p<0.05. 
 
aPL-induced expression of miR-146a-3p induces trophoblast IL-8 secretion 
through activation of TLR8 
 
Recent data suggest that isomiRs can have widely varying targets and both synergistic 
and antagonistic functions within the same cell (101,105). Thus, it remains plausible that 
aPL-induced miR-146a-5p and miR-146a-3p act on different targets within the 
trophoblast. In recent years, some miRs have been found to act outside of the canonical 
role of mRNA degradation and translational repression by directly interacting with 
proteins to alter function (106). Indeed, this evidence provides the foundation for a novel 
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hypothesis suggesting that certain miRs may act in a non-classical fashion by binding 
and activating protein receptors. One protein receptor capable of binding small single-
stranded RNAs (ssRNA) like miRs is TLR8. TLR8 is an endosomal TLR expressed by 
both immune cells (107) and first trimester trophoblast (108), and is typically responsible 
for the detection of ssRNA derived from viruses such as influenza and human 
immunodeficiency virus (107). Similar to TLR4, TLR8 recruits MyD88 upon activation 
and initiates a signaling cascade carried by IRAK1 and TRAF6, ending in transcription of 
NF-κB dependent genes (35). Thus, TLR8 is capable of inducing robust inflammatory 
responses. Indeed, others have recently identified the ability of miR-21 and miR-29a to 
bind and activate TLR8, resulting in NF-κB induction (109). Moreover, let-7 has been 
associated with activation of TLR7, a predominantly murine RNA-sensing TLR closely 
related to human TLR8 (110). Given our observation that miR-146a-3p inhibition reduces 
trophoblast IL-8 in response to aPL, we postulated that aPL trigger this inflammatory 
response through the upregulation of miR-146a-3p and subsequent activation of TLR8 
within the same cells. To test this, we compared the IL-8 secretory responses of wildtype 
and TLR8-DN trophoblast cells to both aPL and exogenous miR-146a-3p. As shown in 
Figure 5A, treatment of wildtype trophoblast cells with aPL resulted in a 2.1 fold increase 
in IL-8 secretion (p<0.05) and this was significantly and almost completely inhibited by 
the presence of the TLR8-DN. Similarly, in the absence of aPL, transfection of wildtype 
trophoblast cells with the miR-146a-3p mimic resulted in a significant 1.6 fold increase in 
IL-8 secretion compared to the miR scramble control (p<0.05) (Figure 5B), and this 
response was completely eliminated in the presence of the TLR8-DN (Figure 5B). These 
results suggest that aPL may induce IL-8 secretion through miR-146a-3p-dependent 
activation of TLR8.   
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Figure 5. aPL and miR-146a-3p induce trophoblast IL-8 secretion in a TLR8 
dependent manner. Wildtype and TLR8-dominant negative (TLR8-DN)-expressing 
trophoblast (HTR-8) were (A) treated with or without aPL (20µg/mL) (n=3); or (B) 
transfected with either a miR scramble control or miR-146a-3p precursor (200nM) 
(n=4). After 72h cell-free supernatants were measured for IL-8 by ELISA. Data were 
analyzed (A) by student’s t test and expressed as fold change (FC) compared to the 
untreated control *p<0.05; or (B) by ANOVA; *p<0.05 vs. the scramble control unless 
otherwise indicated. 
 
 
 
aPL-mediated inhibition of trophoblast migration is independent of miR-155 and 
miR-210 
aPL are known to reduce trophoblast migration (32), which is thought to contribute to the 
pathogenesis of APS (32,81). Indeed, recent studies by our group showed that aPL 
reduce trophoblast invasion and interactions with endothelial cells using a model of 
spiral artery transformation (111). Moreover, this aPL-mediated reduction in trophoblast 
migration is TLR4-independent (32). Recently, miR-155 and miR-210 have been shown 
to be dysregulated in placentae from pathologic pregnancies (112,113), and 
overexpression of trophoblast miR-155 and miR-210 reduces cell migration (89,96). 
Since we found that aPL upregulate expression of both miR-155 and miR-210 
independent of TLR4, we hypothesized that aPL may regulate trophoblast migration 
through these miRs. Thus, we investigated the effects of miR-155 and miR-210 inhibition 
on trophoblast migration in the presence of aPL using a two-chamber colorimetric 
migration assay. As previously reported (32), exposure to aPL significantly reduced 
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trophoblast migration by 70.0% (Figure 6A) and 60.0% (B) as compared to the untreated 
scramble control (p<0.05). However, transfection of specific inhibitors of miR-155 or 
miR-210 had no effect on this aPL-mediated inhibition of migration (Figure 6).  
 
 
Figure 6. aPL-inhibited trophoblast migration is independent of miR-155 and miR-
210 . Trophoblast cells  (HTR8) were transfected with a miR scramble control or either 
(A) a miR-155 inhibitor (α-miR-155; 100nM) (n=3), or (B) a miR-210 inhibitor (α-miR-
210; 100nM) (n=4). Cells were then placed in the upper chamber of a two chamber 
migration assay and were treated with either no treatment (NT) or aPL (20µg/mL). After 
48h in culture, migration across an 8µm pore was determined. Data are expressed as 
% migration normalized to the NT control, which was then set to 100%. *p<0.05 as 
determined by ANOVA. 
 
Vitamin D reduces aPL-induced trophoblast IL-8 secretion  
Since LMWH, the current therapy for pregnant APS patients, does not reduce the risk of 
late gestational complications, there remains a serious need for discovery of new 
therapeutic targets and treatments for obstetric APS. Vitamin D, an immunomodulatory 
hormone, has been implicated in the pathogenesis of APS and is commonly deficient in 
APS patients (73), and thus represents a possible candidate for treating or preventing 
APS. Therefore, in the translational arm of this study, we sought to examine the effects 
of vitamin D exposure on human first trimester trophoblast responses to aPL. As 
previously reported (30,45,46), exposure of HTR8 cells to aPL for 72h resulted in a 
significant increase in IL-8 and IL-1β secretion (Figure 7). The presence of vitamin D 
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significantly reduced aPL-induced IL-8 secretion by 24.9 ± 4.6% (Figure 7A; p<0.05). In 
contrast, vitamin D had no significant effect on the ability of the aPL to upregulate 
trophoblast HTR8 secretion of IL-1β (Figure 7B). Neither vitamin D alone (Figure 7), nor 
the ethanol control (data not shown) had any effect on HTR8 IL-8 or IL-1β secretion. 
 
  
Figure 7. Effect of aPL and vitamin D on a trophoblast cell line secretion of IL-8 
and IL-1β. HTR8 trophoblast cells were incubated with no treatment (NT), active 
vitamin D (Vit D), aPL or both aPL + Vit D. Supernatants were measured for IL-8 and 
IL-1β by ELISA. *p<0.05 relative to the NT control unless otherwise indicated as 
determined by ANOVA. 
 
In previous studies we have found that the aPL, ID2, also modulates HTR8 angiogenic 
factor production. Specifically, ID2 increases HTR8 secretion of the pro-angiogenic 
factor PlGF and the anti-angiogenic factor sEndoglin, while either decreasing or having 
no effect on anti-angiogenic sFlt-1. This aPL (ID2) also had either no effect or a mild 
stimulatory impact on HTR8 secretion of the VEGF (44-46). As shown in Figure 8, the 
presence of vitamin D had no significant effect on the secretion of (A) sEndoglin, (B) 
sFlt-1, (C) PlGF or (D) VEGF in the presence of the aPL. Vitamin D did, however, 
significantly reduce basal HTR8 secretion of sFlt-1 by 26.7±7.8% (Figure 8B). 
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Figure 8. Effect of aPL and vitamin D on a trophoblast cell line secretion of 
angiogenic factors. HTR8 trophoblast cells were incubated with no treatment (NT), Vit 
D, aPL or aPL + Vit D. Supernatants were analyzed for the anti-angiogenic factors, 
sEndoglin and sFlt-1 and the pro-angiogenic factors, PlGF and VEGF by ELISA. 
*p<0.05 relative to the NT control as determined by ANOVA. 
 
Vitamin D inhibits trophoblast aPL-induced miR-146a-5p expression 
 
Vitamin D has recently been found to have numerous immunomodulatory effects, and 
the trophoblast express the vitamin D receptor and key enzymes required for activating 
and deactivating vitamin D (69). Since miR-146a-3p drives trophoblast IL-8 secretion in 
response to aPL (Figure 5), we postulated that vitamin D may inhibit trophoblast IL-8 
secretion through regulation of miR-146a-3p and miR-146a-5p. As shown in Figure 9A, 
vitamin D significantly reduced aPL-induced miR-146a-5p expression from 2.15 fold to 
1.23 fold (p<0.05). While a similar trend was observed with respect to miR-146a-3p, the 
effect of vitamin D did not reach significance. Vitamin D alone did not affect miR-146a-5p 
or miR-146a-3p expression (Figure 9).  
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Figure 9. Vitamin D reduces aPL-mediated miR-146a-5p expression. Trophoblast 
cells were treated with either no treatment (NT) or aPL (20µg/mL) in the presence or 
absence of Vitamin D (10nM). After 48h in culture, RNA was isolated and analyzed for 
(A) miR-146a-5p and (B) miR-146a-3p via qPCR using snU6 as an internal control. 
Data were analyzed by ANOVA and expressed as fold change (FC) compared to the 
NT control. n=4, p*<0.05. 
 
Vitamin D and LMWH inhibit aPL-induced inflammation in primary trophoblast 
cells 
While LMWH is the standard of care for pregnant APS patients, it has been shown to 
have both beneficial and deleterious effects on human trophoblast responses to aPL 
(44,46,58). Thus, we next sought to examine the effects of LMWH and vitamin D, alone 
or in combination, on aPL-mediated trophoblast responses. We previously reported that 
pravastatin exerts different effects on trophoblast responses to aPL when using either 
the HTR8 cell line or primary first trimester trophoblast cells (47). Based on this, and 
since we had only tested the effects of aPL in the presence of LMWH using the HTR8 
cell line (44,46,58), we moved to a primary human first trimester trophoblast culture 
system. As shown in Figure 10A, and consistent with previous reports, aPL significantly 
increased primary trophoblast IL-8 secretion (30). In contrast, in the presence of vitamin 
D and/or LMWH, aPL did not significantly increase IL-8 secretion when compared to the 
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no treatment (NT) control (Figure 10A). Furthermore, neither treatment alone or in 
combination significantly reduced IL-8 secretion compared to aPL alone (Figure 10A). 
Thus, combination of vitamin D and LMWH did appear to reduce aPL-induced IL-8 
secretion to near baseline levels (Figure 10A). The levels of IL-1β secreted from primary 
trophoblast cell in the presence of aPL were significantly reduced by LMWH and vitamin 
D both alone and in combination by 77.3±7.1%, 99.8±0.2% and 95.3±4.2%, respectively 
(Figure 10B). 
 
Figure 10. Effect of LMWH and Vitamin D on aPL-induced secretion of IL-8 and IL-
1β by primary trophoblast cells. Primary human first trimester trophoblast cells were 
incubated with no treatment (NT), aPL, or aPL with LMWH, Vit D, or a combination of 
LMWH + Vit D. Supernatants were analyzed for IL-8 and IL-1β by ELISA. *p<0.05 
relative to the NT control unless otherwise indicated, as determined by ANOVA. 
 
Vitamin D reduces LMWH-induced sFlt-1 release from primary first trimester 
trophoblast cells 
We next sought to evaluate the impact of LMWH and vitamin D, alone and in 
combination on primary trophoblast angiogenic factor production in the presence of aPL. 
Shown in Figure 11A aPL had no effect on sEndoglin secretion by primary trophoblast 
(44), and this was not altered by the presence of LMWH, vitamin D or both compounds. 
Similarly, aPL had no effect on VEGF secretion when compared to the NT control 
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(Figure 11D). However, aPL in the presence of vitamin D, either alone or in combination 
with LMWH, did significantly elevate VEGF secretion when compared to the NT control 
and when compared to cell treated with aPL and LMWH (Figure 11D). aPL significantly 
increased primary trophoblast PlGF secretion and this was not altered by LMWH or 
vitamin D (Figure 11C). Lastly, aPL in the presence of LMWH elevated sFlt-1 release by 
2.4±0.4 fold when compared to aPL alone, and this was significantly reduced to near 
baseline levels when vitamin D was also present (Figure 11B).  
 
 
Figure 11. Effect of LMWH and Vitamin D on aPL-induced modulation of 
angiogenic factors by primary trophoblast cells. Primary human first trimester 
trophoblast cells were incubated with no treatment (NT), aPL, or aPL with LMWH, Vit 
D, or a combination of LMWH + Vit D. Supernatants were analyzed for the anti-
angiogenic factors, sEndoglin and sFlt-1 and the pro-angiogenic factors, PlGF and 
VEGF by ELISA. *p<0.05 relative to the NT control unless otherwise indicated as 
determined by ANOVA. 
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DISCUSSION  
 
Women with obstetric APS are at increased risk of both early pregnancy loss and late 
gestational pregnancy complications such as preeclampsia and fetal growth restriction, 
in addition to the risk of vascular thrombosis (1,3). It is now well established from both 
clinical and experimental observations that these complications are caused by 
inflammatory processes and altered trophoblast function at the maternal-fetal interface 
(27-30,32,43,114). While the mechanisms underlying aPL-mediated trophoblast 
dysfunction have come to light in recent years, much remains unclear and current 
therapies remain unable to prevent dangerous complications related to APS. Therefore, 
further elucidation of the mechanisms by which aPL cause placental dysfunction is 
needed in order to develop therapeutic strategies to prevent both fetal and maternal 
complications of APS.  
 
Since aPL are present in the circulation before conception, it is likely that alteration of 
trophoblast function occurs at the earliest stages of pregnancy. For this reason, we 
focused our study on the effects of aPL on first trimester trophoblast, using both primary 
cultures and a human trophoblast cell line that has been well-characterized by our lab 
and others (30,44,115). The anti-β2GPI monoclonal antibodies (aPL) used in these 
studies have also been shown to behave similarly to patient-derived polyclonal IgG with 
anti-β2GPI activity (30,32,43,44), therefore providing a valid and robust experimental 
system in which to analyze both mechanism and function.  
 
It is now known that anti-β2GPI antibodies are capable of binding the trophoblast and 
inducing functional changes through TLR4 and their downstream signaling pathways 
(30). Classically, the end result of TLR activation is the production of inflammatory 
cytokines that function to recruit immune cells responsible for fighting infection (35). 
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Indeed, trophoblast cells have been shown to produce cytokine and chemokine 
responses capable of recruiting immune cells (116) and evidence of neutrophil infiltrate 
has been seen in APS miscarriage samples (27,116), as well as in a mouse model of 
aPL-induced pregnancy loss (29). Thus, it appears the trophoblast plays a key role in 
both placental innate immune-like responses and communication with the maternal 
immune system. Moreover, aberrant activation of the trophoblast may give rise to an 
altered immune microenvironment at the maternal-fetal interface, resulting in pregnancy 
complications. Since excessive inflammation can damage tissues, tight regulation of 
immune responses is critical to prevent infection, while maintaining placental and 
immune function that is capable of supporting pregnancy.  
 
Since their discovery, miRs have emerged as important regulators of gene expression. 
Indeed, individual miRs can target hundreds of genes, and many miRs that target TLR 
signaling elements have been discovered (82). Moreover, their dynamic, highly 
regulated nature makes them well suited to a level of control over the intensity, timing 
and duration of intracellular signaling that is required for mounting an immune response. 
It is now known that miRs both target and are induced by TLR signaling, and many miRs 
have been directly implicated in trophoblast function (89,96,112). To date, however, little 
is known about how exposure to aPL impacts miR expression and function, and no 
information exists as to whether miRs regulate responses to aPL in the trophoblast. 
Herein, we describe for the first time that aPL, through TLR4, induce the expression of 
trophoblast miR-146a-3p, which in turn drives IL-8 secretion through a novel, TLR8-
dependent mechanism. Notably, we add to a small, yet growing body of literature that 
supports the existence of biologically functional isomiRs.  
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Since aPL induce trophoblast inflammation through activation of the TLR4/MyD88 
signaling pathway (30), we began our studies by examining a small panel of miRs known 
to be involved in the regulation of TLR signaling. Indeed, we found that miR-146a-5p, 
miR-155, and miR-210 were all significantly upregulated by exposure to aPL. We also 
found that miR-146a-3p, the less abundant and thus understudied isomiR of miR-146a, 
was also upregulated in response to aPL. The response was specific to these miRs, as 
aPL did not significantly alter expression of miR-9 or let-7c. Furthermore, the most 
significant upregulation of these miRs occurred at the 48h time point. While this is late in 
comparison to miR responses in other systems, trophoblast responses to aPL are 
typically slow, with end function changes being seen at 72h (30,114). By treating 
trophoblast cells in the presence of aPL with the TLR4 competitive antagonist LPS-RS, 
we observed a significant partial inhibition of aPL-induced miR-146a-5p and miR-146a-
3p, suggesting that aPL-induced expression of both miR-146a isomiRs is TLR4-
mediated. Similar trends were observed with respect to miR-155 and miR-210, however 
these did not reach statistical significance. These observations are in keeping with 
current literature, with miR-146a-5p and miR-155 being two of the most commonly 
induced miRs by TLRs and also the best characterized (82,117).  Moreover, in other 
systems, induction of miR-146a-5p and miR-155 has been shown to be dependent on 
NF-κB activation, the final step in TLR4 signaling (117). In a landmark study, Taganov et 
al. were the first to describe TLR-induced miRs and showed that miR-146a-5p 
expression is regulated by NF-κB and induced by a number of TLR-stimulating microbial 
components such as Poly(I:C), LPS and peptidoglycans, as well as by pro-inflammatory 
cytokines (85). Importantly, through in silico and reporter gene studies, they illustrated 
that miR-146a-5p targets IRAK1 and TRAF6, two adapter proteins critical to TLR and 
cytokine signaling. Taken together, these data support a role for TLR-induced miRs as 
part of a feedback loop that controls TLR-dependent signaling.  
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In an effort to better understand the functional role of aPL-induced miR expression, we 
utilized a transfection system to introduce specific miR inhibitors and mimics into HTR8 
cells. Since miR-146a-5p and miR-146a-3p upregulation illustrated TLR4 dependence, 
we initially focused our functional studies on these miRs. End function changes were 
then analyzed by measurement of IL-8 secretion, a well-characterized product of TLR4 
signaling in response to aPL (30,32). With respect to miR-146a-5p, transfection of a 
specific inhibitor did not result in a change in aPL-induced IL-8 secretion, whereas the 
addition of a miR-146a-3p inhibitor resulted in a significant decrease in aPL-mediated IL-
8 secretion compared to the scramble control. Taken together, these experimental data 
suggest that miR-146a isomiRs are not functioning classically in the trophoblast in the 
context of aPL exposure, since the inhibition of miR-146a-5p would be expected to result 
in unrestrained TLR4 signaling activity and thus increased IL-8 secretion. An alternative 
explanation suggests that aPL-induced TLR4 activation exceeds the ability of 
endogenous miR-146a-5p to negatively regulate the pathway, such that further, 
experimental inhibition of miR-146a-5p activity is not detectable. However, the reduction 
in IL-8 secretion by miR-146a-3p inhibition provides strong evidence that miR-146a-3p is 
functionally active in the trophoblast as part of a pro-inflammatory mechanism, clearly 
distinct from the canonical role of miR-146a-5p in the negative feedback of TLR4 
signaling (85,118). It is well-known that miR expression and function can be highly 
tissue-specific (119), and recent data suggests that miRs, such as miR-155, and their 
respective isomiRs can have opposing effects on TLR-induced inflammation, with one 
isomiR promoting inflammatory signaling and the other dampening it (105). While miRs 
serving as positive regulatory molecules is a relatively novel concept, a number of 
groups have identified miRs that induce inflammation through a novel mechanism by 
binding to and activating TLRs themselves. First described by Fabbri et al., the 
endosomal, single-stranded RNA-sensing receptor TLR8 can bind miR-21 and miR-29a, 
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resulting in activation of inflammatory signaling (109). They illustrated for the first time 
that miRs can reach TLR-containing endosomes and associate with TLR8 in monocytes 
and dendritic cells, resulting in functional activation of the receptor (109).  
 
Thus, we decided to test the hypothesis that aPL-induced miR-146a-3p aberrantly 
activates TLR8 in the trophoblast. To accomplish this, we compared the IL-8 secretion of 
wildtype and TLR8-DN HTR8 cells treated with aPL or a miR-146a mimic. Indeed, our 
results demonstrate that both aPL-mediated and miR-146a-3p-mediated trophoblast IL-8 
secretion is dependent on TLR8, as the presence of the TLR8-DN (94) resulted in 
complete inhibition of the IL-8 response. This suggests that aPL may induce 
inflammation in the trophoblast by upregulating expression of miR-146a-3p through 
TLR4, which subsequently binds and activates TLR8, leading to increased secretion of 
IL-8. This finding is in keeping with recent studies reporting that miR-146a promotes 
TNFα and TGF-β1 production in endothelial cells (120), and that aPL-induced 
inflammation in monocytes is dependent on TLR8 (121). Furthermore, Printz et al. have 
shown that aPL-mediated induction of inflammatory cytokines in monocytes is 
dependent on RNAs, as introduction of RNAses into the culture medium abolishes all 
inflammatory effects of aPL (122). Interestingly, these reports also noted that aPL 
upregulates both expression of TLR8 as well as its translocation to the endosome, 
where it becomes functional. Indeed, this sensitization effect in combination with 
increased miR-146a-3p expression may synergistically facilitate miR-146a-3p-mediated 
TLR8 activation. Taken together, these results suggest a novel mechanism of aPL-
induced trophoblast inflammation, and further supports the concept that miRs may 
induce functional change through endogenous activation of ssRNA-sensing TLRs, like 
TLR8. To our knowledge, we demonstrate for the first time a functional role of the isomiR 
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miR-146a-3p, reinforcing the need to address both mature forms of a miR, regardless of 
abundance, when studying miRs in a physiological context.  
 
Since decidual invasion and migration are impaired in APS pregnancies (27), and aPL 
are known to reduce trophoblast migration independently of TLR4 (30), we sought to 
evaluate whether aPL-mediated regulation of TLR4-independent miRs were responsible 
for these effects. Since we demonstrated that miR-155 and miR-210 were upregulated in 
response to aPL independently of TLR4, and these miRs have been independently 
shown to negatively regulate trophoblast migration (95,96), we transfected trophoblast 
cells with inhibitors to miR-155 and miR-210 and observed the effects on migration in the 
context of aPL. In our study, there was no rescue of migration by inhibition of either miR-
155 or miR-210 alone (Figure 6) or in combination (data not shown), suggesting that aPL 
impair trophoblast migration independently of these miRs. However, work in HTR8 cells 
by another group has shown that miR-155 targets cyclin D1, a protein involved for 
controlling proliferation and migration (95). In their study, overexpression of miR-155 
resulted in decreased expression levels of cyclin D1 and an associated inhibition of 
migration. miR-210 has been shown by others to be upregulated by LPS and 
subsequently downregulate iron-sulfur cluster scaffold homologue, leading to decreased 
trophoblast invasion (123). Thus, while it remains plausible that miR-155 and miR-210 
play a role in regulating trophoblast migration and invasion, aPL-mediated inhibition of 
these functions likely occur through alternate mechanisms.  
 
Without treatment, women with APS are at high risk of pregnancy loss and late 
gestational obstetric complications, including preeclampsia. Despite conflicting data from 
clinical trials, pregnant women with APS are routinely treated with LMWH (51,54,124). 
While this therapy might be successful in maintaining a viable pregnancy, it does not 
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appear to reduce the risk of associated late gestational complications (22,23,48). 
Heparin therapy was introduced under the assumption that recurrent pregnancy loss in 
APS patients was due to thrombosis, however, it has become clear that aPL-associated 
adverse pregnancy outcomes are primarily pro-inflammatory rather than pro-thrombotic 
(27-30,125), and that heparin might be acting through mechanisms other than 
anticoagulation (30,46,52). Indeed, these extended actions of LMWH may even have 
detrimental effects by significantly increasing placental and circulating levels of sFlt-1 
(44,46,60-62), a potent anti-angiogenic factor that is elevated in preeclampsia (63) and 
promotes preeclamptic symptoms in animal models of pregnancy (64,126). Thus, there 
remains a need for the development and/or identification of therapeutics that can reduce 
both the recurrent pregnancy loss and the late gestational complications associated with 
APS, either alone or in combination with the current therapeutic approaches. 
 
Vitamin D, a steroid hormone now recognized for its immunomodulatory properties, has 
been shown to be deficient in APS patients compared to controls (73). Vitamin D 
deficiency may also be associated with adverse pregnancy outcomes such as 
preeclampsia and recurrent pregnancy loss (77-80). Indeed, the placenta is a major site 
for conversion of vitamin D into its active form, 1,25-Dihydroxyvitamin D3 (71). 
Furthermore, vitamin D has been directly implicated in the pathogenesis of APS by its 
ability to inhibit anti-β2GPI antibody-mediated tissue factor expression (73). Taken 
together, these data support a role for vitamin D in the treatment of pregnant APS 
patients. In the translational arm of this study, we show for the first time that active 
vitamin D is able to both regulate aPL-mediated inflammation and mitigate LMWH-
induced sFlt-1 release in human first trimester trophoblast.  
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For this part of the study, both the HTR8 trophoblast cell line and primary human first 
trimester trophoblast cultures were utilized. Previous work from our group has revealed a 
number of effects of aPL on human first trimester trophoblast function using both cellular 
models; in particular the increased secretion of the pro-inflammatory 
cytokines/chemokines, IL-8 and IL-1β; and altered angiogenic factor production (30,43-
47). Thus, we first sought to assess the effects of vitamin D alone on aPL-mediated 
trophoblast responses using HTR8 cells. Since we previously reported that pravastatin 
exerts different effects on trophoblast responses to aPL when using either the HTR8 cell 
line or primary trophoblast cells (47), we also investigated the impact of vitamin D both 
alone and in combination with LMWH on aPL-mediated effects using primary cultures. 
 
Indeed, we found that treatment of HTR8 cells with vitamin D alone attenuated aPL-
mediated IL-8 secretion. In the primary cultures, LMWH inhibited aPL-induced IL-1β 
secretion, confirming previous studies in the HTR8 cell line (46). Moreover, vitamin D 
either alone, or in combination with LMWH, completely inhibited the aPL-induced IL-1β 
response, while combination LMWH and vitamin D appeared to attenuate the IL-8 
response. This suggests that vitamin D both alone and in combination with LMWH may 
be acting to regulate aPL-induced inflammatory signals in the trophoblast. Studies in 
human lymphocytes and a melanoma cell line have demonstrated the ability of vitamin D 
to downregulate IL-8 release by repressing NF-κB signaling (127,128) and active vitamin 
D has been shown to suppress decidual natural killer cell cytokine production (129). 
Moreover, studies in mice have shown that vitamin D, through activation of the vitamin 
D-activating enzyme 1α-hydroxylase (CYP27B1), can reduce LPS-induced placental 
inflammation. This suggests that vitamin D can regulate TLR4-mediated inflammatory 
responses (71). Since aPL induce human trophoblast IL-8 and IL-1β production through 
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activation of the TLR4 signaling pathway (30,43), vitamin D may be acting to suppress 
trophoblast inflammation induced by aPL in this manner.  
 
It is also possible that vitamin D exerts its anti-inflammatory activity through the 
regulation of miRs. Indeed, the vitamin D receptor is regulated by miRs and vitamin D 
has been shown to alter miR expression in numerous cell types (130-132), although the 
effects of vitamin D on trophoblast miR expression have yet to be studied. Since aPL-
mediated miR-146a-3p expression promotes trophoblast IL-8 secretion, we postulated 
that vitamin D reduces the aPL-induced IL-8 response through downregulation of miR-
146a-3p. To that end, we investigated the effects of vitamin D on trophoblast expression 
of both miR-146a isomiRs, and found that treatment with vitamin D reduces aPL-induced 
miR-146a-5p expression. While a similar trend was observed, miR-146a-3p expression 
was not significantly inhibited by vitamin D. Thus, our results do not support the 
hypothesis that vitamin D decreases trophoblast inflammation through downregulation of 
miR-146a-3p. Rather, our data suggests that vitamin D may reduce aPL-mediated IL-8 
secretion and miR-146a-5p expression. Thus, vitamin D may inhibit TLR8 function and 
miR-146a-5p may have an as yet undetermined function in the trophoblast. Indeed, a 
recent study in monocytes showed that vitamin D suppresses TLR8-mediated IL-1β and 
TNFα expression in response to the TLR8 ligands, ssRNA and CL075 (133). While 
further study is warranted, these data provide further support for a role of vitamin D in 
regulating responses to aPL, and that vitamin D may have a direct impact on trophoblast 
TLR4 and TLR8 pathways.   
 
In addition to inflammatory factors, we also examined the ability of vitamin D to modulate 
aPL-mediated changes in angiogenic factor secretion. Proper placentation depends on 
appropriate vascular development and remodeling, which is controlled by both maternal- 
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and placental-derived angiogenic factors (134). These factors are tightly regulated in 
normal pregnancy, and thus aberrant expression of angiogenic factors may negatively 
impact placentation and subsequent pregnancy outcomes. Indeed, pro- and anti-
angiogenic factors are dysregulated in APS patients (135-137), as well as locally and 
systemically in pregnant women with preeclampsia (63,138-141). Furthermore, the 
combination of low vitamin D levels with sFlt-1/PlGF ratios has been shown to provide 
better prediction of severe preeclampsia than either marker alone (142). Herein, we 
show that aPL significantly upregulated secretion of sEndoglin and PlGF in the HTR8 
cell line, and PlGF in the primary trophoblast cells as previously reported (44), 
reinforcing the potential of aPL to dysregulate placental angiogenic factor secretion. 
While vitamin D did not have any overt impact on aPL-mediated modulation of 
angiogenic factors in the trophoblast cell line, we noted that it significantly reduced sFlt-1 
release.  
 
In order to assess the potential of vitamin D to be used as an adjuvant therapeutic for 
pregnant APS patients, we tested the effects of vitamin D both alone and in combination 
with standard of care treatment, LMWH, on primary trophoblast function in the presence 
of aPL. Again, vitamin D either alone or in combination with LMWH did not have any 
overt impact on aPL-mediated modulation of angiogenic factors in the primary 
trophoblast. However, vitamin D did appear to promote trophoblast VEGF secretion, and 
recent studies in endothelial progenitor cells have shown that vitamin D can promote 
VEGF expression (143). In this study, we reconfirmed previous findings that LMWH 
significantly promotes sFlt-1 release from the trophoblast (44,46), as well as from 
placental villus explants (60-62). Moreover, the presence of vitamin D significantly 
inhibited this LMWH-induced sFlt-1 release to near-baseline levels. Since studies have 
implicated sFlt-1 in the pathogenesis of preeclampsia (63,64,126), this finding supports 
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the potential of vitamin D to be used in addition to LMWH to help prevent negative 
effects of LMWH administration.  
 
The mechanism by which LWMH affects sFlt-1 release and how vitamin D regulates this 
process remains unclear. There is evidence that sFlt-1 is induced by EGFR1 pathway 
transactivation in endothelial cells (144), while others suggest that circulating sFlt-1 
levels are controlled by regulated release from extracellular stores (62). Thus, vitamin D 
may be counteracting the effects of LMWH through multiple mechanisms. One possible 
mechanism is through parallel antagonism of pro-angiogenic pathways, evidenced by 
the ability of vitamin D to upregulate VEGF production through vitamin D-mediated 
VEGF gene promotion (145). Alternatively, vitamin D may work through regulation of 
extracellular enzymes responsible for sFlt-1 release.  
 
Thus, our findings suggest a beneficial role for vitamin D supplementation in pregnant 
patients with APS, as its effects both alone and in combination with LMWH counteract 
the inflammatory effects of aPL on the trophoblast. While vitamin D alone reduces aPL-
mediated functional changes, the capacity to reduce LMWH-mediated sFlt-1 release is 
even more promising, given the direct implications of elevated sFlt-1 in the pathogenesis 
of preeclampsia. Altogether, this work supports further investigation into the role that 
vitamin D plays in both trophoblast function, and in the development and treatment of 
obstetric APS.  
 
The primary limitation affecting the generalizability of this study is the use of the HTR8 
trophoblast cell line and monoclonal anti-β2GPI antibodies, without support from primary 
cultures and/or patient-derived aPL. While the use of this experimental system provides 
a clean platform for functional analysis, the results cannot be readily applied to an in vivo 
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setting. It is now known that the immortalization technology used to produce the HTR8 
cell line can introduce mutations that may cause untoward, non-physiologic effects, 
calling into question data gained from experiments using these cells. However, our lab 
has directly compared the aPL-mediated responses between HTR8 cells and primary 
cultures in previous work, finding them to behave similarly (30,114). Thus, while 
experiments using an alternative first trimester trophoblast cell line, such as Sw.71 or 
3A, as well as primary cultures and patient-derived aPL would reinforce the data 
described here, we believe that our experimental system provides an excellent 
foundation for the study of signaling pathways in the trophoblast and that our findings 
warrant further study in more extensive explant or murine models of APS. Furthermore, 
while illustrated in other trophoblast cell lines (69), we recognize that the presence of the 
vitamin D receptor and associated activating enzymes in HTR8 cells has not yet been 
confirmed. While our observations suggest that the vitamin D machinery is functional 
within this cell line, confirmation of VDR and CYP27B1 expression as well as functional 
studies using either siRNA knockdown or dominant negative signaling elements will 
further strengthen our results. Another limitation to this work is the reliance on synthetic 
miR mimics and inhibitors to assess miR function. The commercial mimics and inhibitors 
used in this study are broadly used and provide excellent evidence of the functional roles 
of miRs in a given system, however it is difficult to establish the biological relevance of a 
miR in vivo as they are naturally highly dynamic regulators of expression and have the 
capacity to affect multiple targets within a single cell. Thus, while our data strongly 
suggests a functional role of miR-146a, further work is warranted in determining its exact 
relevance in the trophoblast and the development of APS.    
 
In summary, we present here new insights into the mechanisms by which aPL induce 
inflammation and altered function in the trophoblast, and also the ability of vitamin D to 
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partially reverse these negative effects. We also describe further evidence of a novel 
mechanism by which TLR8 is activated by an endogenous miR, miR-136a-3p, and that 
in our system this is induced by aPL. More broadly, we contribute to the growing 
literature on miR and isomiR function, especially within the trophoblast. This work 
provides the foundation for further study into the concept of miRs as ligands of TLRs and 
protein receptors, and the biochemical evaluation of how this process occurs, so that 
other miRs with similar functions may be discovered more efficiently through in silico 
analysis. Finally, this study provides insight into the pathophysiology of APS and further 
confirms the inflammatory and autoimmune nature of the disease. Imminent work from 
our lab will seek to examine miR-146a levels within the serum and placentae of patients 
with APS, which may serve both clinically as a potential diagnostic or prognostic 
biomarker for APS and associated gestational complications, as well as 
pathophysiologically, providing further implication of miR-146a in the development of 
APS. Indeed, miR-146a is only the first of many miRs to be involved in the 
pathophysiology of APS and the placenta, and future study into the function of miRs is 
bound to lead to a better understanding of APS, the immune system and human 
physiology.  
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